



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

The a2 Milk Company Limited (ATM)
27-Aug-2026
06-Nov-2025

Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Kevin Bush
The a2 Milk Company Limited
N/A
Managing Director - USA

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):

(1) Unlisted performance rights (Performance Rights) representing an entitlement to acquire fully paid ordinary shares in ATM (Ordinary Shares). (2) Ordinary Shares.
Spouse of registered holder and beneficial owner.

For that relevant interest-

Number held in class before acquisition or disposal:
--

(1) 309,023 Performance Rights of which: (a) 138,297 are due to vest on a date to be determined by the Board following the release of ATM's full year audited results for FY2026 provided certain performance conditions are met; (b) 105,531 are due to vest on a date to be determined by the Board following the release of ATM's full year audited results for FY2027 provided certain performance conditions are met; and (c) 65,195 are due to vest on a date to be determined by the Board following release of ATM's full year audited results for FY2028 provided certain performance conditions are met. (2) 251,021 Ordinary Shares.

Number held in class after acquisition or disposal:	(1) 170,726 Performance Rights of which: (a) 105,531 are due to vest on a date to be determined by the Board following the release of ATM's full year audited results for FY2027 provided certain performance conditions are met; and (b) 65,195 are due to vest on a date to be determined by the Board following release of ATM's full year audited results for FY2028 provided certain performance conditions are met. (2) 349,557 Ordinary Shares.
Current registered holder(s):	(1)(a) Jennifer O'Brien <Kevin Bush A/c> (1)(b) & (c) Kevin Bush (2) Jennifer O'Brien <Kevin Bush A/c> holds 64,196 Ordinary Shares and Kevin Bush holds 186,825 Ordinary Shares.
Registered holder(s) once transfers are registered:	(1)(a) & (b) Kevin Bush (2) Jennifer O'Brien <Kevin Bush A/c> holds 162,732 Ordinary Shares and Kevin Bush holds 186,825 Ordinary Shares.

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	N/A
Class of underlying financial products:	

Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	1
---	---

Details of transactions requiring disclosure-

Date of transaction:	20-Aug-2026
----------------------	-------------

Nature of transaction:	Vesting and automatic exercise of 138,297 Performance Rights resulting in the transfer of 98,536 Ordinary Shares to Jennifer O'Brien <Kevin Bush A/c> and retention of 39,761 Ordinary Shares on account of US income tax, social security and Medicare withholding obligations.
Name of any other party or parties to the transaction (if known):	a2 ESS Holdings Pty Limited as trustee for a2 Group Employee Share Trust (transferor of Ordinary Shares)
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	Nil
Number of financial products to which the transaction related:	(1) 138,297 Performance Rights (2) 98,536 Ordinary Shares
<i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>	
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	N/A
Date of the prior written clearance (if any):	N/A


Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:	N/A
Nature of relevant interest:	
<i>For that relevant interest,-</i>	
Number held in class:	
Current registered holder(s):	
<i>For a derivative relevant interest,-</i>	
Type of derivative:	

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	18 August 2026

or

Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:
